FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120051737> ?p ?o ?g. }

• W3120051737 endingPage "2257" @default.
• W3120051737 startingPage "2243" @default.
• W3120051737 abstract "Abstract Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia (AML) has in principle been shown to be a T cell-sensitive disease by the graft-versus-leukemia activity of allogeneic stem cell transplantation, T cell therapy has so far failed in this setting. This is largely due to the lack of target structures both sufficiently selective and uniformly expressed on AML, causing unacceptable myeloid cell toxicity. To address this, we developed a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML. This platform combines synthetic agonistic receptor (SAR) -transduced T cells with AML-targeting tandem single chain variable fragment (scFv) constructs. Construct exchange allows SAR T cells to be redirected toward alternative targets, a process enabled by the short half-life and controllability of these antibody fragments. Combining SAR-transduced T cells with the scFv constructs resulted in selective killing of CD33 + and CD123 + AML cell lines, as well as of patient-derived AML blasts. Durable responses and persistence of SAR-transduced T cells could also be demonstrated in AML xenograft models. Together these results warrant further translation of this novel platform for AML treatment." @default.
• W3120051737 created "2021-01-18" @default.
• W3120051737 creator A5002737974 @default.
• W3120051737 creator A5003069482 @default.
• W3120051737 creator A5011253702 @default.
• W3120051737 creator A5011277242 @default.
• W3120051737 creator A5013500913 @default.
• W3120051737 creator A5019951356 @default.
• W3120051737 creator A5024997588 @default.
• W3120051737 creator A5034401637 @default.
• W3120051737 creator A5036493478 @default.
• W3120051737 creator A5036710605 @default.
• W3120051737 creator A5043031466 @default.
• W3120051737 creator A5046414258 @default.
• W3120051737 creator A5046946936 @default.
• W3120051737 creator A5047983915 @default.
• W3120051737 creator A5050281853 @default.
• W3120051737 creator A5057494468 @default.
• W3120051737 creator A5060341147 @default.
• W3120051737 creator A5067162282 @default.
• W3120051737 creator A5076903946 @default.
• W3120051737 creator A5084094076 @default.
• W3120051737 creator A5086659894 @default.
• W3120051737 date "2021-01-07" @default.
• W3120051737 modified "2023-10-17" @default.
• W3120051737 title "A modular and controllable T cell therapy platform for acute myeloid leukemia" @default.
• W3120051737 cites W144898347 @default.
• W3120051737 cites W1631320694 @default.
• W3120051737 cites W1975427849 @default.
• W3120051737 cites W1976174066 @default.
• W3120051737 cites W1985561195 @default.
• W3120051737 cites W1990602451 @default.
• W3120051737 cites W2000715091 @default.
• W3120051737 cites W2003539449 @default.
• W3120051737 cites W2004004651 @default.
• W3120051737 cites W2008748351 @default.
• W3120051737 cites W2013971016 @default.
• W3120051737 cites W2015956932 @default.
• W3120051737 cites W2022881751 @default.
• W3120051737 cites W2026205985 @default.
• W3120051737 cites W2028069487 @default.
• W3120051737 cites W2035990435 @default.
• W3120051737 cites W2044088883 @default.
• W3120051737 cites W2058817033 @default.
• W3120051737 cites W2065709542 @default.
• W3120051737 cites W2067094969 @default.
• W3120051737 cites W2077994554 @default.
• W3120051737 cites W2080170460 @default.
• W3120051737 cites W2095426672 @default.
• W3120051737 cites W2097175022 @default.
• W3120051737 cites W2112364188 @default.
• W3120051737 cites W2128736714 @default.
• W3120051737 cites W2145444883 @default.
• W3120051737 cites W2160026729 @default.
• W3120051737 cites W2161955458 @default.
• W3120051737 cites W2205658382 @default.
• W3120051737 cites W2233225245 @default.
• W3120051737 cites W2258336271 @default.
• W3120051737 cites W2316323341 @default.
• W3120051737 cites W2408097265 @default.
• W3120051737 cites W2556754806 @default.
• W3120051737 cites W2558279374 @default.
• W3120051737 cites W2587691649 @default.
• W3120051737 cites W2591709377 @default.
• W3120051737 cites W2761657464 @default.
• W3120051737 cites W2761903029 @default.
• W3120051737 cites W2768664841 @default.
• W3120051737 cites W2768823259 @default.
• W3120051737 cites W2787301955 @default.
• W3120051737 cites W2790486786 @default.
• W3120051737 cites W2793887515 @default.
• W3120051737 cites W2800187318 @default.
• W3120051737 cites W2805058565 @default.
• W3120051737 cites W2807921412 @default.
• W3120051737 cites W2811405063 @default.
• W3120051737 cites W2864786814 @default.
• W3120051737 cites W2895336021 @default.
• W3120051737 cites W2908717823 @default.
• W3120051737 cites W2922471907 @default.
• W3120051737 cites W2924339726 @default.
• W3120051737 cites W2946717294 @default.
• W3120051737 cites W2947751606 @default.
• W3120051737 cites W2948141873 @default.
• W3120051737 cites W2952168835 @default.
• W3120051737 cites W2961062447 @default.
• W3120051737 cites W2985236105 @default.
• W3120051737 cites W2990164885 @default.
• W3120051737 cites W3000497625 @default.
• W3120051737 doi "https://doi.org/10.1038/s41375-020-01109-w" @default.
• W3120051737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7789085" @default.
• W3120051737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33414484" @default.
• W3120051737 hasPublicationYear "2021" @default.
• W3120051737 type Work @default.
• W3120051737 sameAs 3120051737 @default.
• W3120051737 citedByCount "22" @default.
• W3120051737 countsByYear W31200517372021 @default.
• W3120051737 countsByYear W31200517372022 @default.
• W3120051737 countsByYear W31200517372023 @default.

• next